

Non replicating viral vector - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	19 studies ¹	-	-	0.20 [0.02 ; 1.72], 1 RCT, I2=0% inconclusive result	-
Janssen AD26 vaccine (JNJ-78436735)	9 studies ²	-	-	0.19 [0.04 ; 0.81], 1 RCT, I2=0% certainty unassessable	-
CanSino (Convidecia)	3 studies ³	-	-	-	-
Sputnik V (Gam-COVID-Vac)	2 studies ⁴	-	-	-	-
Covishield (Oxford/AZ formulation)	1 study ⁵	-	-	-	-

Notes

¹Asano, 2022 (NCT04568031); Com-COV2, 2022 (ISRCTN 27841311); AstraZeneca phase 3 US (D8110C00001), 2021 (NCT04516746); AstraZeneca phase 3 US (D8110C00001) 6 month follow up, 2021 (NCT04516746); Com-COV, 2021 (ISRCTN69254139); AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)*safety*, 2020(); *ChAdOx1phase3(AstraZeneca)*, 2020(NCT04400838); *AstraZenecaOx.Cox*, 2021(); *Husby(Astra)*, 2021(); *Patone*, 2021(); *Simpson(ChAdOx1)*, 2021(); *Bernal(PHE, 19thFebruary2021)*, 2021(); *Burn(Vaxzevria)*, 2021(); *Edward(Vaxzevria)*, 2021(); *Bernal*, 0(); *Pottegard*, 2021()

²Reindl-Schwaighofer, 2021 (); Sadoff, 2021 (NCT04436276); ENSEMBLE (COV3001), 0 (NCT04505722); MixNMatch Study, 2021 (NCT04889209); Botton (EPI-PHARE), 2022 (); EPIPHARE (Janssen), 2022 (); Husby (janssen), 2021 (); Pawlowski, 2021 (); Sisonke 2 (booster), 2021 (NCT05148845)

³Li J, 2022 (NCT04892459); Fengcai, 2021 (NCT04566770); CanSino phase 2 (Zhu), 2020 (NCT04341389)

⁴RESIST (Sputnik V Gamaleya Research Institute Russia), 2020 (NCT04530396); Nabirova, 2022 ()

⁵Kulkarni, 2021 (CTRI/2020/08/027170)